SimianX AI LogoSimianX AI

Primärquellen-Eintrag

EntscheidungsrelevantTopline-Ergebnisse

AbbVie: Positive Phase-3-Topline-Daten der LUNA-Studie zu Atogepant bei menstrueller Migräne

Phase 3 LUNA study met its primary endpoint and all eight ranked secondary endpoints, showing statistically significant reduction in perimenstrual migraine days versus placebo. AbbVie plans to submit these data to health authorities worldwide and present findings at future medical congresses.

Kernfakten

Eingereicht
10. Sept. 2026, 12:55
Ereignis
Topline-Ergebnisse
Richtung
Positiv
Unternehmen
ABBVAbbVie
Asset
atogepant
Quelle
Unternehmensmitteilung
Belegstatus
Belegt
p-Wert
p<0.0001
Migränetag-Reduktion
1,20 vs 0,40 Tage
Placebo-adjustierte Reduktion
0,80 Tage

Auszug aus der Quelle

AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine News provided by AbbVie Sep 10, 2026, 08:55 ET Share this article Share to X Share this article Share to X Menstrual migraine is a recurrent, debilitating migraine pattern, with attacks occurring around or during the menstrual period, a predictable time of increased biological vulnerability 2,4 Atogepant demonstrated statistically significant reductions in migraine days associated with the menstrual period, meeting the primary and all eight ranked secondary endpoints versus placebo in the Phase 3 LUNA study (p<0.0001) 1 No treatment options are currently approved for menstrual migraine, u

Unternehmensmitteilung

Mehr zu diesem Asset